Vijay Chiruvolu
Chief Tech/Sci/R&D Officer bij TURNSTONE BIOLOGICS CORP.
Vermogen: - $ op 31-03-2024
Profiel
Vijay Chiruvolu is currently the Chief Technology Officer at Turnstone Biologics Corp.
Prior to this, he was the Chief Technical Officer at Instil Bio, Inc. from 2020 to 2022.
He also held the position of Senior Vice President-Process Development at Kite Pharma, Inc. Dr. Chiruvolu holds an MBA from The Pennsylvania State University and a doctorate from The University of Nebraska-Lincoln.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 19-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Vijay Chiruvolu
| Bedrijven | Functie | Begin |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Chief Tech/Sci/R&D Officer | 01-03-2023 |
Eerdere bekende functies van Vijay Chiruvolu
| Bedrijven | Functie | Einde |
|---|---|---|
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 02-09-2022 |
| KITE PHARMA INC | Corporate Officer/Principal | - |
Opleiding van Vijay Chiruvolu
| The Pennsylvania State University | Masters Business Admin |
| The University of Nebraska-Lincoln | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
| Turnstone Biologics Corp. |
